Audiological assessment and otoacoustic emissions in patients with head and neck cancer
Avaliação audiológica e emissões otoacústicas em pacientes com câncer de cabeça e pescoço
Pâmela Fukazawa; Sarah da Silva Santos; Raquel Caroline Ferreira Lopes Fontanelli; Daniela Gil
Abstract
Purpose: to describe the audiological and otoacoustic emission findings in patients who had head and neck cancer and compare them with individuals without the disease.
Methods: a comparative, cross-sectional, observational study encompassing two groups: Study: individuals with a history of head and neck cancer, submitted to chemotherapy and/or radiotherapy; Control: individuals without the disease. The sample comprised 23 individuals in each group, matched for age and gender. Procedures in which the groups were compared: meatoscopy; pure-tone threshold and highfrequency audiometry; speech audiometry; transient-evoked otoacoustic emissions. Statistical tests: Pearson’s chi-square; Fisher’s exact; two-proportion Z-test; Wilcoxon; Mann-Whitney; Student’s t-test.
Results: the comparison between the groups revealed statistically significant differences at the 3, 6, 8, 10, and 12.5 kHz frequencies in the pure-tone threshold audiometry, with better pure-tone auditory thresholds in the control group. No significant differences were observed between the groups in the otoacoustic emissions regarding the general response and frequency band.
Conclusion: individuals with a history of head and neck cancer had higher pure-tone auditory thresholds than their controls, especially at the higher frequencies. This evidences the deleterious effect of ototoxicity on the peripheral auditory system of adults. The otoacoustic emissions were similar in the two groups.
Keywords
Resumo
Objetivo: descrever os achados audiológicos e das emissões otoacústicas em pacientes com câncer de cabeça e pescoço e compará-los com indivíduos sem a doença.
Métodos: estudo observacional transversal comparativo realizado em dois grupos: Estudo: indivíduos com histórico de câncer de cabeça e pescoço submetidos à quimioterapia e/ou radioterapia; Controle: indivíduos sem a doença. A amostra foi composta por 23 indivíduos em cada grupo, pareados considerando idade e gênero. Procedimentos: meatoscopia; audiometria tonal liminar e de altas frequências; logoaudiometria e emissões otoacústicas evocadas transientes, comparados entre os grupos. Testes estatísticos: Qui-quadrado de Pearson; exato de Fisher; igualdade de duas proporções; Wilcoxon; Mann-Whitney e t de Student.
Resultados: a comparação entre os grupos revelou diferença estatisticamente significante nas frequências de 3, 6, 8, 10 e 12,5kHz na audiometria tonal liminar, com melhores limiares auditivos tonais no grupo controle. Não foram observadas diferenças significantes entre os grupos nas emissões otoacústicas, quanto a resposta geral e banda de frequência.
Conclusão: indivíduos com histórico de câncer de cabeça e pescoço apresentam limiares auditivos tonais mais elevados do que seus controles, sobretudo nas frequências altas, evidenciando o efeito deletério da ototoxicidade no sistema auditivo periférico de adultos. As emissões otoacústicas mostraram-se semelhantes nos dois grupos.
Palavras-chave
Referencias
1. Lydiatt WM, Patel SG, O'Sullivan B, Brandwein MS, Ridge JA, Migliacci JC et al. Head and neck cancers - major changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual. CA Cancer J Clin. 2017;67(2):122-37.
2. Instituto Nacional de Câncer José Alencar Gomes da Silva, Copyright © 1996 – 2016 INCA – Ministério da Saúde. [cited 2019 Jul18] Available from: http://www2.inca.gov.br/wps/wcm/connect/tiposdecancer/site/home/laringe
3. Licitra L, Bernier J, Grandi C, Locati L, Merlano M, Gatta G, Lefebvre JL. Cancer of the larynx. Critical Reviews in Oncology/Hematology. 2003;47(1):65-80.
4. Wünsch V. The epidemiology of laryngeal cancer in Brazil. Sao Paulo Med. J. 2004;122(5):188-94.
5. Vilar CMC, Martins IM. Câncer de cabeça e pescoço. In: Vieira SC, Lustosa AML, Barbosa CNB, Teixeira JMRT, Brito LXE, Soares LFM et al. (eds). Oncologia básica. 1. ed. Teresina, PI: Fundação Quixote, 2012. p.9-22.
6. Vilar CMC, Martins IM. Princípios de cirurgia oncológica. In: Vieira SC, Lustosa AML, Barbosa CNB, Teixeira JMRT, Brito LXE, Soares LFM et al. (eds). Oncologia básica. 1. ed. Teresina, PI: Fundação Quixote, 2012. p.221-36.
7. Crisanto MLLP. Princípios de Quimioterapia. In: Vieira SC, Lustosa AML, Barbosa CNB, Teixeira JMRT, Brito LXE, Soares LFM, Ferreira MAT et al. (eds). Oncologia básica. 1. ed. Teresina, PI: Fundação Quixote, 2012. p.237-52.
8. Oliveira PF, Oliveira CS, Andrade JS, Santos TFC, Oliveira-Barreto AC. Tratamento oncológico na determinação das alterações auditivas. Braz. j. otorhinolaryngol. 2016;82(1):65-9.
9. Rosenberg B, Van Camp L, Krigas T. Inhibition of cell division in escherichia coli by electrolysis products from a platinum electrode. Nature. 1965;205(4972):698-9.
10. Abdollahi H, Mostafaei S, Cheraghi S, Shiri I, Mahdavi SR, Kazemnejad A. Cochlea CT radiomics predicts chemoradiotherapy induced sensorineural hearing loss in head and neck cancer patients: A machine learning and multi-variable modeling study. Phys Med. 2018;45:192-7.
11. Hyppolito MA, Oliveira JAA. Ototoxicidade, otoproteção e autodefesa das células ciliadas da cóclea. Medicina. 2005;38(3/4):279-89.
12. Garcia AP, Iório MCM, Petrilli AS. Monitoramento da audição de pacientes expostos à cisplatina. Rev. Bras. Otorrinolaringol. 2003;69(2):215-21.
13. Ng SP, Pollard C, Berends J, Ayoub Z, Kamal M, Garden AS et al. Usefulness of surveillance imaging in patients with head and neck cancer who are treated with definitive radiotherapy. Cancer. 2019;125(11):1823-9.
14. Schultz C, Goffi-Gomez MV, Liberman PH, Carvalho AL. Report on hearing loss in oncology. Braz. j. otorhinolaryngol. 2009;75(5):634-41.
15. Jacob LCB, Aguiar FP, Tomiasi AA, Tschoeke SN, Bitencourt RF. Monitoramento auditivo na ototoxicidade. Rev. Bras. Otorrinolaringol. 2006;72(6):836-44.
16. Fausti SA, Frey RH, Henry JA, Olson J, Schaffer HI. High-frequency testing techniques and instrumentation for early detection of ototoxicity. Journal Rehabilitation Res Development. 1993;30(3):333-41.
17. Damian PI, Valverde TA, Guimarães DP, Gil D. Auditory monitoring in adults undergoing chemotherapy with carboplatin. Distúrb Comum. 2017;29(3):438-47.
18. Dunckley KT, Dreisbach LE. Gender effects on high-frequency distortion product otoacoustic emissions in humans. Ear Hear. 2004;25(6):554-64.
19. Littman TA, Magruder A, Strother DR. Monitoring and predicting ototoxic damage using distortion-product otoacoustic emissions: pediatric case study. J Am Acad Audiol. 1998;9(4):257-62.
20. Yardley MP, Davies CM, Stevens JC. Use of transient evoked otoacoustic emissions to detect and monitor cochlear damage caused by platinum-containing drugs. Br J Audiol. 1998;32(5):305-16.
21. Almeida EOC, Costa CB, Oliveira SPT, Umeoka MTH. Audiometria tonal e emissões otoacústicas – produtos de distorção em pacientes tratados com cisplatina. Arq. Int. Otorrinolaringol. 2006;10(3):203-8.
22. American Speech-Language-Hearing Association. (1988). Determining threshold level for speech [Guidelines]. [cited 2019 Nov29] Available from: www.asha.org/policy.
23. Lloyd L, Kaplan H. Audiometric interpretation: a manual of basic audiometry. Press, 1978.
24. Finitzo T, Albright K, Oneal J. The newborn with hearing loss: detection in the nursery. Pediatrics. 1998;102(6):1452-60.
25. American Cancer Society. Clinical Oncology. Atlanta: ACS; 2001.
26. Menezes M. Efeitos da radioterapia sobre a audição em pacientes portadores de tumores de cabeça e pescoço [monografia]. Recife (PE): CEFAC; 1999.
27. Yasui N, Adachi N, Kato M, Koh K, Asanuma S, Sakata H et al. Cisplatin-induced Hearing Loss. J Pediatr Hematol Oncol. 2014;36(4):e241-5.
28. Driessen CML, Leijendeckers J, Snik A, Graaf WTA, Boer JP, Gelderblom H et al. Ototoxicity in locally advanced head and neck cancer patients treated with induction chemotherapy followed by intermediate or high-dose cisplatin-based chemoradiotherapy. Head & Neck. 2019;41(2):488-94.
Submitted date:
23/07/2019
Accepted date:
08/06/2020
Facebook
Twitter
LinkedIn
Mendeley
Email